An urgently needed new tuberculosis vaccine cleared a vital step in testing, an important advance at time when a third of the world's population is believed to be have latent tuberculosis infection (LTBI), which, when re-activated, can cause full-blown disease. The results of the Phase I trial of a leading new TB vaccine, MVA85A, appeared in the April 15th issue of the American Journal of Respiratory and Critical Care Medicine.